Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTR1E | P28566 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5665179 | 0.86 | — | — | |
| SCHEMBL14470862 | 0.81 | KDM4E (0.48) | KDM4ELMNAGAACHRM3MEN1 | |
| Cadaverine Tartrate SCHEMBL2322051 | 0.80 | DUT (0.45) | KDM4ELMNADPP4GAAKMT2A | |
| SCHEMBL10840120 | 0.80 | KMT2A (0.39) | KDM4ELMNADPP4KMT2ATSHR | |
| SCHEMBL7593196 | 0.78 | CHRM3 (0.55) | KDM4ECHRM3 | |
| SCHEMBL14453327 | 0.78 | GPR119 (0.44) | KDM4E | |
| SCHEMBL17109642 | 0.78 | SLC6A2 (0.52) | KDM4ECHRM3 | |
| SCHEMBL4575056 | 0.77 | KMT2A (0.42) | LMNADPP4GAACHRM3KMT2A | |
| SCHEMBL220309 | 0.75 | KDM4E (0.45) | KDM4ELMNAGAACHRM3MEN1 | |
| SCHEMBL3644854 | 0.75 | CHRM3 (0.51) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241082-A1 | Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease | FLECKENSTEIN ANNETTE E | 2006-10-26 | — | — | US | disclosed |
| WO-2004101476-A1 | METATHESIS REACTION INVOLVING THE UNSATURATED SIDE CHAIN OF AN ALPHA, ALPHA-DISUBSTITUTED AMINO ACID | DSM IP ASSETS B.V. (NL) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004026258-A2 | MODULATING VESICULAR MONOAMINE TRANSPORTER TRAFFICKING AND FUNCTION: A NOVEL APPROACH FOR THE TREATMENT OF PARKINSON’S DISEASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241082-A1 | Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease | SLC18A2, SLC18A3, SLC6A3 | KDM4E 3482/4885LMNA 4533/4885DPP4 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.